Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes

Antzeko izenburuak

• Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes
  nork: Atkin, S, et al.
  Argitaratua: (2011)
• The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
  nork: Meneghini, L, et al.
  Argitaratua: (2013)
• Type 2 Diabetics, insulin degludec administered once/daily according to a flexible schema assured glycemic control similar to a daily administration according to a fixed hour schema without augmenting hypoglycemic episods
  nork: Raccah, D, et al.
  Argitaratua: (2012)
• Efficacy and tolerance of insulin degludec administered once/day in a pattern unique flexible compared to insulin glargine once daily at a fixed time in patients with type 2 diabetes (T2D)
  nork: Huet, D, et al.
  Argitaratua: (2012)
• Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
  nork: Lyudmila Alexandrovna Suplotova, et al.
  Argitaratua: (2015-12-01)